Reactive Oxygen Species: From Tumorigenesis to Therapeutic Strategies in Cancer
Cancer Medicine · 2025-05 · 14 (10)
DOI: 10.1002/cam4.70947 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 16.05.2025. Verfasst von Iqra Attique und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Kinnaird College for Women University, Lahore, Pakistan. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Neoplasms, Carcinogenesis, Antineoplastic Agents. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 240 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar National Library.
Abstract (Originalsprache)
Background
Reactive oxygen species (ROS), a class of highly reactive molecules, are closely linked to the pathogenesis of various cancers. While ROS primarily originate from normal cellular processes, external stimuli can also contribute to their production. Cancer cells typically exhibit elevated ROS levels due to disrupted redox homeostasis, characterized by an imbalance between antioxidant and oxidant species. ROS play a dual role in cancer biology: at moderate levels, they facilitate tumor progression by regulating oncogenes and tumor suppressor genes, inducing mutations, promoting proliferation, extracellular matrix remodeling, invasion, immune modulation, and angiogenesis. However, excessive ROS levels can cause cellular damage and initiate apoptosis, necroptosis, or ferroptosis.
Methods
This review explores molecular targets involved in redox homeostasis dysregulation and examines the impact of ROS on the tumor microenvironment (TME). Literature from recent in vitro and in vivo studies was analyzed to assess how ROS modulation contributes to cancer development and therapy.
Results
Findings indicate that ROS influence cancer progression through various pathways and cellular mechanisms. Targeting ROS synthesis or enhancing ROS accumulation in tumor cells has shown promising anticancer effects. These therapeutic strategies exhibit significant potential to impair tumor growth while also interacting with elements of the TME.
Conclusion
The ROS serve as both promoters and suppressors of cancer depending on their intracellular concentration. Their complex role offers valuable opportunities for targeted cancer therapies. While challenges remain in precisely modulating ROS for therapeutic benefit, they hold promise as synergistic agents alongside conventional treatments, opening new avenues in cancer management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, Kinnaird College for Women University, Lahore, Pakistan.
- Department of Biotechnology, Lahore College for Women University, Lahore, Pakistan.
- Department of Botany, Kinnaird College for Women University, Lahore, Pakistan.
- Clinical Laboratory Sciences Department, Turabah University College, Taif University, Taif, Saudi Arabia.
- Biochemistry Department, Faculty of Veterinary Medicine, Benha University, Toukh, Egypt.
- Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
ORCID-Profile: Mohamed Mohamed Soliman, Wisam Nabeel Ibrahim
Förderung
- Qatar National Library
Zitieren
APA
Attique, I., Haider, Z., Khan, M., Hassan, S., Soliman, M. M., Ibrahim, W. N., & Anjum, S. (2025). Reactive Oxygen Species: From Tumorigenesis to Therapeutic Strategies in Cancer. Cancer Medicine, 14(10). https://doi.org/10.1002/cam4.70947
Vancouver
Attique I, Haider Z, Khan M, Hassan S, Soliman MM, Ibrahim WN, et al. Reactive Oxygen Species: From Tumorigenesis to Therapeutic Strategies in Cancer. Cancer Medicine. 2025;14(10). doi:10.1002/cam4.70947
BibTeX
@article{Attique2025,
author = {Attique, Iqra and Haider, Zahra and Khan, Maha and Hassan, Samina and Soliman, Mohamed Mohamed and Ibrahim, Wisam Nabeel and Anjum, Sumaira},
title = {Reactive Oxygen Species: From Tumorigenesis to Therapeutic Strategies in Cancer},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {10},
doi = {10.1002/cam4.70947}
}
EUVIMED